Archives
-
Interpreting ROS Assays: What the Study Shows
2026-10-11
Miwa and colleagues found that carboxylesterases can convert Amplex Red to resorufin without hydrogen peroxide or horseradish peroxidase, complicating some mitochondrial H₂O₂ measurements. The study raises an assay-specific validity concern, but it does not directly evaluate SOD activity assays or the APExBIO kit.
-
dual-enSERT: In Vivo Testing of Enhancer Variants
2026-10-10
Hollingsworth and colleagues introduce dual-enSERT, a Cas9-based two-color reporter framework for comparing human enhancer alleles in the same live mouse. The study shows that the system can detect gain- and loss-of-function activity, connect enhancer misregulation with cell-state-specific transcriptional programs, and prioritize rare or common non-coding variants for further investigation.
-
OCT2 and MATE1 Inhibition by 5-HT3 Antagonists
2026-10-09
George and colleagues compared five 5-HT3 antagonist drugs for their ability to inhibit renal OCT2- and MATE1-mediated organic-cation transport in complementary cell models. The study identifies substantial differences between compounds and shows that transporter inhibition can reduce epithelial secretion in vitro, while also emphasizing that these findings do not by themselves establish clinical drug interactions.
-
From Enhancer Variants to Translational Evidence
2026-10-09
A thought-leadership analysis of how dual-enSERT connects non-coding variant discovery with cell-type-aware functional interpretation, and where labeled nucleotides such as Biotin-16-dCTP may support adjacent analytical workflows.
-
SGI-1027 and Everolimus in Renal Cancer
2026-10-08
A 2024 Advanced Science study reports that the DNMT1 inhibitor SGI-1027 cooperates with everolimus to suppress renal cancer models while engaging lysosomal membrane permeabilization, apoptosis, and GSDME-dependent pyroptosis. The findings suggest a mechanistic strategy for addressing everolimus resistance, although the evidence remains primarily preclinical and requires validation across additional models.
-
APEX2, TERT Expression, and Stem Cell DNA Repair
2026-10-08
A 2024 bioRxiv preprint identifies APEX2, but not its paralog APEX1, as a factor required for efficient TERT expression in human embryonic stem cells and a melanoma model. Its RNA-seq and chromatin-binding evidence suggests that repair-associated repetitive DNA regions, particularly MIR elements within TERT, may connect DNA damage responses with gene regulation.
-
2-Thio-dCTP: From DNA Chemistry to Chromosome Biology
2026-10-07
Explore how 2-Thio-dCTP and 2-Thio-2'-deoxycytidine-5'-Triphosphate can support mechanistic DNA studies without being mistaken for direct probes of histone phosphorylation. This evidence-focused guide connects nucleotide chemistry with the 2026 SCP4 chromosome-stability study while defining practical interpretation limits.
-
Reserpine (N1867) Product Overview
2026-10-07
Supplier-reported identity, catalog specifications, conceptual research scope, and evidence limitations for Reserpine (SKU N1867).
-
Ambroxol Targets Nav1.8, TRPV1 and TRPA1
2026-10-06
A 2025 Journal of Pain study examined how ambroxol modulates human and rat Nav1.8 channels and human TRPV1 and TRPA1 receptors in vitro. Its main contribution is a mechanistic framework for topical analgesia that emphasizes species dependence, channel state, and multi-target sensory-neuron pharmacology rather than assuming selective Nav1.8 inhibition.
-
HRP Goat Anti-Mouse IgG (H+L): Product Overview
2026-10-06
APExBIO’s K1221 is described as an affinity-purified, polyclonal goat anti-mouse IgG (H+L) secondary antibody conjugated to horseradish peroxidase. No matched paper evidence was provided, so this overview is limited to documented product identity and stated conceptual scope.
-
APOE, Macrophages, and PTC Progression
2026-10-05
A 2024 Immunobiology study links elevated APOE expression with papillary thyroid carcinoma progression and an M2-like macrophage phenotype. Its central contribution is a tumor–immune mechanism connecting APOE, the PI3K/Akt/NF-κB axis, anti-inflammatory cytokines, and macrophage behavior, while its cell and xenograft models define important boundaries for interpretation.
-
Tropisetron Hydrochloride: A Transporter Lens
2026-10-05
Tropisetron Hydrochloride is more than a 5-HT3 receptor antagonist: it also provides a useful model for examining how receptor pharmacology intersects with renal transporter biology. This article separates established findings from interpretation and explains what OCT2 and MATE1 data can—and cannot—show.
-
p-Tau Ser356 and NUAK Inhibition in Alzheimer’s
2026-10-04
Taylor et al. characterize tau phosphorylated at serine 356 as a pathology-associated epitope that increases with Alzheimer’s disease Braak stage and localizes near synapses and neurofibrillary tangles. Their ex vivo pharmacology also reveals a species- and culture-dependent response to NUAK inhibition, with selective p-tau Ser356 lowering in human brain slices but broader protein loss in mouse cultures.
-
Cefazedone (Refosporen): From Mechanism to Translation
2026-10-03
A translational perspective on Cefazedone and Refosporen, connecting penicillin-binding protein biology with analytical pharmacokinetics, antibacterial testing in vitro, community-acquired pneumonia research, competitive positioning, and the evidence boundaries that matter for responsible development.
-
Iron-Dependent KDM4D Controls MSC Quiescence
2026-10-01
The 2024 reference study identifies iron-dependent KDM4D demethylase activity as a regulatory link between iron status, PIK3R3 transcription, and the PI3K-Akt-Foxo1 pathway in mesenchymal stem cells. Its findings connect impaired epigenetic control under iron deficiency with defective MSC activation and reduced bone mass, while pathway modulation partially reverses the phenotype.